Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Information by Drug Class

Information by Drug Class

                        Prescription Stimulant Medications


                        Human Immunodeficiency Virus (HIV) Home
          Drugs
          Drug Safety and Availability
          Information by Drug Class
          Prescription Stimulant MedicationsInformation by Drug Class Prescription Stimulant Medications
  
  					Information about FDA's work to support appropriate use and address the impact of stimulant-related risks, including misuse, addiction, overdose, and diversion.
	
    Share
    Post
    Linkedin

    Email
    PrintPrescription stimulants are classified as Schedule II drugs under the Controlled Substances Act and associated with serious risks, including misuse, addiction, overdose, and diversion. Stimulants are an area of great interest given that the number of prescriptions has nearly doubled from 2011 to 2022 (FDA DSC, 2023), with the greatest increase in adults (CDC MMWR, 2023). FDA’s Overdose Prevention Framework strives to address the impact of stimulants-related issues as part of a comprehensive approach to address a public health concern. Using this framework, FDA intends to strike a balance between supporting access to safe and effective medications and preventing the negative consequences of nonmedical use.

**Recent Activities**

FDA Takes Steps to Advance the Development of Novel Therapies for Stimulant Use Disorders
	FDA awards National Academies of Sciences, Engineering, and Medicine (NASEM) with grant toward workshop examining diagnosis and treatment of ADHD in adults
	FDA Requires Updates to Clarify Labeling of Stimulant Medications


Supporting Primary Prevention

When used appropriately, FDA-approved prescription stimulants can provide significant benefits for patients, such as improving attention in people with attention deficit/hyperactivity disorder (ADHD), reducing excessive overeating episodes in people with binge eating disorder, and increasing wakefulness in people with uncontrollable episodes of deep sleep (narcolepsy). FDA has taken important steps to increase access to diverse treatment options for ADHD, including authorization of a game-based digital therapeutic and non-stimulant drug options. FDA is also promoting safe use and appropriate prescribing of stimulants by funding research to inform prevention of prescription stimulant misuse, addiction, and overdose. Additionally, FDA has awarded the National Academies of Sciences, Engineering, and Medicine (NASEM) with a grant toward a workshop that will examine the diagnosis and treatment landscape of ADHD in adults.

FDA Updating Warnings to Improve Safe Use of Prescription Stimulants
	FDA Funds University of Michigan Research Project on Stimulant Use Disorder TrajectoriesEncouraging Harm Reduction

FDA is working to increase awareness about the risks associated with nonmedical use of prescription stimulants. To accomplish this, FDA collaborates with federal partners to educate the public about the risks related to prescription stimulants, including side effects (e.g., anxiety, insomnia) and risk of addiction. Additionally, FDA is funding research with the American College of Medical Toxicology to provide detailed, real-time information on the fourth wave of the overdose crisis and the impact of stimulant co-consumption. Most fatal overdoses involving a stimulant also involve an opioid, and FDA has taken actions to help expand availability of life-saving opioid overdose reversal drugs. To aid this effort, FDA held a public workshop to inform product development and public health interventions to manage overdoses.

FDA Funds Near Real-Time Surveillance of Stimulants in the Overdose Crisis
	Information about Naloxone and Nalmefene
	FDA Hosts Public Workshop to Understand and Manage OverdoseEvidence-Based Treatments for Stimulant Use Disorders

FDA is supporting innovation in treatment development for stimulant use disorders. As there are currently no FDA-approved pharmacological treatments for stimulant use disorders, FDA is working to accelerate their development. Recent efforts include a draft guidance on developing treatments for stimulant use disorders and public workshops.

FDA Takes Steps to Advance the Development of Novel Therapies for Stimulant Use Disorders
	Meeting Summary: A Practical Research Agenda for Developing Stimulant Use Disorder Treatment
	Public Meeting on Patient-Focused Drug Development for Stimulant Use DisorderProtecting the Public from Unapproved, Diverted, or Counterfeit Drugs Presenting Overdose Risks

FDA has developed resources on purchasing prescription medications online through BeSafeRx to help ensure access to medications from a safe source. Additionally, FDA is proactively working to address controlled substances illegally sold online. To reduce the risks presented by excess prescription medication, FDA has developed resources on safe drug disposal.

FDA Consumer Updates: How to Buy Medicines Safely from an Online Pharmacy
	FDA Issues Warning Letters to Website Operators Illegally Selling Prescription Stimulants
	FDA Hosts Summits Focused on Preventing the Illegal Online Opioids SalesRelated Resources

Dealing with ADHD: What You Need to Know
	Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
	FDA Overdose Prevention Framework
	Controlled Substances ProgramResources

Prescription Stimulants
	Educational Tools on Prescription Stimulants
	Treatment of Stimulant Use Disorders
	Prescription Stimulant Misuse Among Youth and Young Adults
	Tips for Teens: The Truth About Stimulants
	CDC Stimulant Guide

                                                                                  Content current as of:
      10/25/2023
              
              
Regulated Product(s)
		 DrugsInformation by Drug Class

          
                        Prescription Stimulant Medications


                        Human Immunodeficiency Virus (HIV)
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop